cons of glp 1 drugs Long-Term Effects GLP-1 Medications: What You Should Know Pros & cons of GLP-1
Description
Important Safety Information for GLP-1 Medications
Recent Findings Retatrutide is the first triple agonist (acting on GLP-1/GIP/glucagon receptors) with published phase 2 data in people with obesity as well as in people with T2D
Recent signals underscore this shift: Eli Lilly became the first pharmaceutical company to surpass a $1 trillion market capitalization [1] buoyed by global demand for obesity medications
What is the association between periconceptional GLP-1 receptor agonist exposure and risk of obstetric complications
Find out who shouldn't take Mounjaro or Wegovy
